Enterprise Bancorp Inc
Change company Symbol lookup
Select an option...
EBTC Enterprise Bancorp Inc
FSLY Fastly Inc
BNR Burning Rock Biotech Ltd
FCNKX Fidelity® Contrafund® Fund Class K
CAT Caterpillar Inc
POAGX PRIMECAP Odyssey Aggressive Growth Fund
VFIFX Vanguard Target Retirement 2050 Fund Investor Shares
CMCSA Comcast Corp
CUZ Cousins Properties Inc
ZM Zoom Video Communications Inc
Go

Financials : Banks | Small Cap Blend
Company profile

Enterprise Bancorp, Inc. operates as the holding company of Enterprise Bank and Trust Company (the Bank). The Company is engaged in the business of gathering deposits from the general public and investing primarily in loans and investment securities and utilizing the resulting cash flows to conduct operations, expand the branch network, and pay dividends to stockholders. Through the Bank and its subsidiaries, the Company offers a range of commercial and consumer loan products, deposit products and cash management services. The Company also offers investment advisory and wealth management, trust and insurance services. The Company offers lending services to business entities, non-profit organizations, professionals and individuals. Loans made to businesses include commercial mortgage loans; construction and land development loans; secured and unsecured commercial loans; lines of credit, and standby letters of credit.

Closing Price
$22.60
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
13,297
0

SRNE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 27, 2020 in the Class Action Filed on Behalf of Sorrento Therapeutics, Inc. Limited Shareholders

6:13 pm ET July 22, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - July 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) alleging that the Company violated federal securities laws.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7092/60338_932901_logo.jpg

Class Period: May 15, 2020 and May 22, 2020

Lead Plaintiff Deadline: July 27, 2020

Learn more about your recoverable losses in DNK:

http://www.kleinstocklaw.com/pslra-1/sorrento-therapeutics-inc-loss-submission-form?id=8116&from=5

The filed complaint alleges that Sorrento Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders have until July 27, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the SRNE lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60338

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.